Angiotensin-converting enzyme (ACE) inhibitors and more recently angiotensin-receptor blockers (ARBs) have become popular therapies in the end-stage renal disease (ESRD) patient. The ability of either of these drug classes to reduce blood pressure in the ESRD patient is well accepted; however, there is considerably less information available to guide the clinician in the safe and effective use of these drugs in the ESRD patient with congestive heart failure and/or coronary artery disease. Head-to-head studies in the ESRD patient are lacking for both drug classes. Several pharmacokinetic factors can influence the selection of these drugs, including dialysability and the propensity for systemic accumulation. ACE inhibitors (ACE-Is) and ARBs are recognised as having a range of nonpressor effects that are pertinent to patients with ESRD. Such effects include their ability to decrease both thirst drive and erythropoiesis. These drug classes, though, are distinguishable by the unique adverse effect profile for ACE-Is. As is the case in patients without renal failure, ESRD patients can experience cough and, less frequently, angioneurotic oedema with ACE-Is. In the ESRD population, so-called anaphylactoid dialyser reactions can occur in conjunction with ACE-I use. The use of a drug from within the ARB class carries both less risk and permits a compound with a preferred pharmacokinetic profile -limited dialysability and minimal systemic accumulation -to be administered. These attributes would favour the increased use of ARBs in this population.
Introduction
In the United States, more than 220,000 patients undergo chronic haemodialysis for end-stage renal disease (ESRD), at an estimated annual cost of 11 billion dollars. 1 Hypertension is one of the most common clinical problems in patients undergoing chronic maintenance haemodialysis and it is estimated that the prevalence of hypertension in this population is as high as 80%. 2, 3 Blood pressure (BP) is often poorly controlled in this population 4, 5 and is one of several factors which contribute to their heightened risk for cardiovascular disease. 6 The large majority of ESRD patients begin renal replacement therapy with a disproportionate burden of cardiovascular disease (CVD) risk factors. 7 These factors, both individually and collectively, argue for therapy with agents that reduce the activity of the renin-angiotensin-aldosterone system (RAAS). To date, the majority of the published experience with RAAS interruption in ESRD has been with angiotensin-converting enzyme (ACE) inhibitors. 8 More recently, angiotensin II (Ang II) receptor blockers (ARBs) have provided a therapeutic alternative to ACE inhibitors (ACE-Is) in this highly vulnerable population. 8 This review summarises the available information on ARBs in the ESRD patient. Because of the limited amount of information on the use of ARBs in this population, the greater body of information available for ACE-Is is drawn on to provide some of the basis for a discussion of this drug class.
Treatment of hypertension
A number of studies have established ARBs as effective therapy in the treatment of ESRD-related hypertension. [9] [10] [11] [12] [13] [14] To date, there have been no pharmacologic studies in a representative sample of ESRD patients, which have explored the concentration-effect relationship for BP reduction with either ARBs or ACE-Is. Small patient cohort studies, either designed to characterise the pharmacokinetics of these drugs in ESRD patients or to specifically treat a hypertensive condition, have shown occasional brisk BP responses, frequently in response to low doses of these compounds. 11, 15, 16 It can be presumed that such responders have a more renin-dependent form of hypertension, although pre-therapy assessment of RAAS activity is not consistently done in many of these studies. Alternatively, if the ESRD-related hypertension is more volume-sensitive and presumably less renindependent, higher doses of an ACE-I or an ARB are probably needed to achieve the desired BP response. 15 Large, open-label trials, such as the Evaluation of the Losartan in Hemodialysis (ELHE) Study, have generally found significant reductions in pre-and post-dialysis systolic and diastolic BP. 17 Two pharmacokinetic properties are of particular relevance to the use of these drug classes in the ESRD patient: first, drug dialysance and second, systemic accumulation with repeat dosing. The dialysance of either an ARB or an ACE-I is a relevant consideration in assessing the BP-lowering response with either of these drug classes (Table 1) . 16, [18] [19] [20] [21] [22] ARBs are typically highly protein bound and as a result poorly dialysable, which makes post-dialysis supplementation of an ARB a moot point. Second, all ARBs undergo a significant amount of hepatic clearance, thus minimising the degree of systemic accumulation with repeat dosing ( Table 2 ).The relevance of drug dialysability (or not) and/or the degree of systemic accumulation with ARBs is at this time undetermined. 8
Access patency
Three studies to date have assessed the effect of ACE-I therapy on access patency rates. In a small study of 30 patients reported by Choudry, 10 of whom were on ACE-I therapy, it was observed that primary patency of polytetrafluoroethylene (PTFE) grafts was significantly better in the ACE-I treated group. 29 A larger observational study assessed arteriovenous fistulae survival among 912 Japanese patients with ESRD, of whom 212 were on ACE-I therapy. The odds ratio for arteriovenous fistula occlusion for the non-ACE-I group was 1.79 when compared with the ACE-I group. 30 Finally, in a retrospectively analysed survey of intervention-free access survival rates (Kaplan-Meier), an ACE-I treated group fared better than a non-ACE-I treated group (71% vs. 53% at six months, 58% vs. 35% at 12 months, and 44% vs. 22% at 24 months; p=0.04). 31 These findings are biologically plausible along several lines of reasoning. Over the last few years, various steps in the pathophysiological process of graft thrombosis have been elucidated. Stenosis at the venous anastomosis, the most common reason for access failure in patients with PTFE grafts, is caused by a myointimal proliferative process. 32 This pathological state is distinguished by intimal hyperplasia, pronounced vascular smooth muscle cell proliferation and migration, and deposition of extracellular matrix surrounding smooth muscle cells in the neointima. This process leads to progressive venous outflow stenosis and eventually to thrombosis of the arterio-venous graft. Ang II has been found to be an important component of these proliferative responses. For example, Ang II has been shown to induce smooth muscle cell proliferation in the injured rat arterial wall. 33 Moreover, cell culture and animal studies have shown that ACE-Is prevent myointimal proliferation and migration. To date, the role of ARBs in graft patency is unknown, although it is reasonable to presume that they would provide similar vascular access benefits as occur with ACE-Is.
Left ventricular hypertrophy
Left ventricular hypertrophy (LVH), which occurs frequently in dialysis patients, is not only a major cardiovascular risk factor for the ESRD patient, but also one of the most powerful predictors of their survival. 34 Anaemia and poorly treated hypertension are the two factors most often coupled to the development of LVH in the ESRD patient. Correction of anaemia by erythropoietin therapy and/or strict BP control will regress LVH in many, but not all patients so afflicted. [35] [36] In addition to an absolute change in left ventricular (LV) mass, the alteration in the specific geometric pattern of the left ventricle might provide additional insight into the likelihood of LV mass regression with various therapies. In this regard, several studies have previously shown ACE-Is to be effective in regressing LVH in haemodialysis patients. [37] [38] [39] In the haemodialysis patient, eccentric LVH appears less responsive to ACE-I treatment and is associated with a greater incidence of adverse cardiovascular events compared with a concentric LVH pattern. Moreover, a decrease in pulse pressure appears to be the main predictor of the regression of LVH in chronic haemodialysis patients on ACE-I therapy. 40 To date, there are a limited number of studies which have examined the effect of ARBs on LV mass regression. 41 Until more extensive studies are conducted,ACE-Is should remain the treatment of choice in the haemodialysis patient when LV mass regression is a sought after endpoint. This being said, it has been suggested that the DD genotype of the ACE gene polymorphism is a contributory factor for the development of LV hypertrophy in patients with ESRD. [42] [43] [44] If this is true, it may be a factor that detracts from the positive effects that attend ACE-I administration and so supports ARB use in the ESRD patient with LV hypertrophy.
Long-term survival
Antihypertensive therapy is common in the ESRD population. Despite the common use of antihypertensives in this population, the optimal goal BP in the hypertensive ESRD patient still remains to be determined.Although never formally studied in a prospective fashion in the ESRD patient, ACE-I use is often advocated on the basis of their favourable effects on cardiac and cerebrovascular 248 REVIEW outcomes, albeit in non-ESRD patients. To date, ARB use for these same purposes has been slow in coming, which may relate to the novelty of this drug class more than anything. Recent reports shed some light on the relationship between ACE-I use and morbidity and mortality in the ESRD patient. [45] [46] [47] [48] [49] Foley et al. evaluated a randomly generated sample of 11,142 subjects receiving haemodialysis on December 31, 1993, and followed their vital status until May 2000. Each antihypertensive drug class, except ACE-Is, was associated with lower mortality in unadjusted models, an effect which was particularly prominent for β-blockers. Comorbidity adjustment eliminated survival associations for each antihypertensive class except β-blockers, where a pronounced effect persisted. 45 In contrast to these findings, Efrati et al. found, in a retrospective analysis of 60 patients, that ACE-I use was associated with an absolute risk reduction for mortality of 79% in those below the age of 65 years. 46, 47 This benefit was independent of the BP-lowering effect of these drugs. Survival benefits were also found with ACE-I therapy in a 150 patient cohort undergoing evaluation for aortic pulse wave velocity over approximately four years. 48 Finally, Kestenbaum et al. did not find an association between the use of ACE-Is, β-blockers, or aspirin and the risk of mortality among ESRD patients. In their study, the use of a calcium channel blocker was associated with a 21% lower risk of total mortality and a 26% lower risk of cardiovascular specific mortality. 49 Taken together, these retrospective reports would seem to convincingly argue for a large-scale randomised trial comparing several of the antihypertensive drug classes as to their morbidity and mortality benefits.
Pharmacodynamics

Treatment of congestive heart failure
Heart failure management in ESRD is complicated, with multiple etiologic factors in play. In this regard, ACE-I or ARB therapy for congestive heart failure (CHF) has not been formally studied in the ESRD population. To date, no long-term outcome studies have been conducted in this population with either of these drug classes, although these drugs are in common use when CHF exists. 50, 51 Although ACE-Is can be presumed to be 'effective' when CHF is present in the ESRD patient, this is by inference alone from studies conducted in non-ESRD CHF populations. It is probable that the alteration in Ang II effect, from either ACE-I or ARB therapy, would offer some therapeutic benefit to the ESRD patient with CHF. However, the level of such benefit can only be speculated on.
Current practice guidelines for the management of CHF recommend high-dose ACE-I therapy if optimal survival benefits are to be achieved. Several studies support this conclusion, though there still remains some debate as to what truly represents a 'high-dose' of ACE-I. 52, 53 A question yet to be resolved is whether the benefits of ACE inhibition are also dose-dependent in the ESRD patient with CHF. This is relevant, since the selection of either an ACE-I or an ARB would then require knowledge of its dialysability, systemic accumulation with repeat dosing, and tolerance in the post-dialysis setting.The latter is a circumstance characterised by a particular susceptibility to BP drops when antihypertensive medications are given.
Thirst
In polydipsic haemodialysis patients, Ang II levels rise after a dialysis session, in part related to the degree of volume removal. 53 Ang II levels can remain elevated in the interdialytic period, despite the progressive volume expansion, which characterises this period. High Ang II levels have been associated with excessive thirst, mediated by either central or peripheral thirst-promoting mechanisms, and large interdialytic weight gains. [54] [55] [56] An important practical implication of these observations is that drugs which decrease RAAS axis activity may reduce the polydipsia observed in these patients. [57] [58] [59] In an early, unblinded trial using captopril, interdialytic weight gain and thirst were diminished in four polydipsic patients. 56 In a more extensive set of studies, employing a double-blind, placebo-controlled, crossover design, enalapril therapy was accompanied by a significant reduction in interdialytic weight gain, thirst, and intake of fluid. These changes occurred in parallel with a significant increase in plasma renin activity, a fall in ACE activity, and decreased concentrations of Ang II. Interestingly, these findings occurred despite a low dose of enalapril, (5 mg twice-weekly). 57 ACE-Is, though, have not uniformly suppressed thirst or a surrogate of intake, interdialytic weight gain, in the ESRD patient, suggesting that thirst drive is more complicated than was originally believed. 58, 60 In the only thirst-related study of ARB therapy, seven chronic haemodialysis patients received losartan for 10 weeks. Only three of the seven patients showed significant reductions in their average interdialytic weight gain. Interdialytic weight gain was directly related to sodium intake in the entire study population and responders had significantly lower Ang II levels. 61 Similar to previous reports relating ACE-I use to thirst, multiple factors appear to influence interdialytic weight gain when ARBs are being administered. Additional clarifying studies will be required to sort out the variety of factors associated with excessive thirst in the dialysis patient, as well as what will constitute the best therapy.
Anaemia
In 1984, nine of a group of 12 hypertensive chronic haemodialysis patients were observed to have a decrease in haemoglobin concentration, haematocrit, and red blood cell mass while undergoing long-term treatment with captopril. 62 The average daily dose of captopril was 27.6 mg in this series. In two of the three patients who did not show worsening of anaemia in this study, an anabolic steroid was being administered. Following discontinuation of the captopril, haematocrit values returned to pretreatment levels. 62 In subsequent studies, it was found that this anaemia was associated with reduced circulating concentrations of Ang II, 63 which paralleled a suppression in erythropoietin production. 64 The observed anaemia in these patients was successfully treated with androgenic steroids despite little change in erythropoietin levels, suggesting an element of 'erythropoietin resistance'. 65 ACE-I-related anaemia seems to be a class effect 66 and has been observed to occur in both haemodialysis 62, 63, 65 and continuous ambulatory peritoneal dialysis patients. 67 The precise mechanism(s) of ACE-Irelated anaemia remain poorly defined in the ESRD patient. It was originally held that ACE-I administration, by increasing renal blood flow and thereby decreasing renal tissue hypoxia, might remove a hypoxic stimulus to erythropoietin release; thus, the observed fall in red blood cell mass. 68 Subsequent studies have suggested that ACE-I-related anaemia in ESRD cannot be explained purely by a decrease in erythropoietin concentrations, 69,70 though the contribution from 'erythropoietin resistance'has proven quite variable. 71, 72 Recent observations provide several mechanisms by which ACE-Is might suppress erythropoiesis. 73, 76 First, ACE-Is reduce circulating insulin-like growth factor-I (IGF-1) and interleukin-12, factors known to stimulate erythropoiesis. 73, 74 Secondly, ACE-Is block the breakdown of the natural stem cell regulator, Nacetyl-seryl-aspartyl-lysyl-proline (AcSDKP), leading to increased circulating concentrations of this tetrapeptide and inhibition of recruitment of pluripotent haematopoietic stem cells. 75 Treatment with ACE-Is can increase levels of AcSDKP by a factor of four, although the levels are partially reduced following a haemodialysis session. 76 ARB administration also appears to inhibit red blood cell production. Like ACE-Is,ARBs can reduce haemoglobin levels in patients with post-transplant polycythaemia. 77, 78 Both ACE-Is and ARBs can be expected to behave similarly in the setting of posttransplant polycythaemia, since the inappropriately high levels of erythropoietin in this condition derive from Ang II-stimulated erythropoiesis, which is blocked equally well by either of these drug classes. The situation in erythropoietin-treated patients, in whom suppression of endogenous erythropietin production is irrelevant, may be more related to AcSDKP. Since ARBs should not increase the concentration of AcSDKP, there is a basis for differing effects of each drug class on red blood cell production. Unfortunately, there are much more limited data on the effect of ARBs on erythropoietin responsiveness than there are for ACE-Is. 79, 83 Schwarzbeck et al. were the first to suggest that losartan aggravated anaemia in dialysis patients, 79 an observation disputed by Lang and Schiffl. 80 In support of the observations of Lang and Schiffl, 80 Chew et al. conducted a prospective, double-blind, placebo-controlled, crossover study examining the effect of 25 mg losartan on the action of erythropoietin in 14 patients and found no difference between losartan and placebo. 81 Similarly, Saracho et al. reported no adverse haematologic effects in 324 haemodialysis patients receiving at least 12 months' therapy with losartan. 17 In comparing ACE-I and ARB-treated ESRD patients, differing effects on haematologic parameters emerge. 82, 83 Schiffl and Lang compared the effects of losartan and captopril in two groups of 12 dialysis patients, employing a prospective randomised study design. Captopril-treated patients required higher doses of erythropoietin to maintain the same target haemoglobin level, compared with the group receiving losartan. 82 Kato et al. studied 25 haemodialysis patients who received either temocapril or losartan for 12 months. 83 Haemoglobin values dropped and rHuEPO doses increased in the temocapril-treated patients, but remained stable in those treated with losartan.
It is tempting to speculate that the reason for these differences was that the ACE-I increased AcSKDP levels, causing erythropoietin resistance. Whether true differences exist between ACE-I and ARBs in the ability to affect erythropoiesis remains to be determined. Until that time, ACE-Is should remain the preferred compounds for suppression of erythropoiesis when this is a desired effect, as in the case of post-transplant erythrocytosis. In dialysis patients who develop 'resistance' to rHuEPO while on an ACE-I, the evidence, albeit limited, would support substituting an ARB for an ACE-I.
Side-effects Cough
Cough is one of the more frequent side-effects associated with ACE-I therapy. 84 Whether cough is more frequent in ESRD patients being treated with ACE-Is is currently not known. It is fairly well accepted that the frequency of cough with ARBs is little different than that observed with placebo. 85, 86 This applies to the use of ARBs in either essential hypertensives 85, 86 or in patients with ESRD. 17 The absence of cough with ARBs is one of the unquestioned advantages of this drug class over ACE-Is.
Angioneurotic oedema
Angioneurotic oedema is a potentially fatal adverse effect, which can have multiple aetiologies, including ACE-Is and ARBs. It was originally thought that ARB use would not be associated with angioneurotic oedema, since these drugs did not interfere with bradykinin metabolism. Shortly after the release of ARBs, though, sporadic reports began to appear, describing angioedema as a complication. These reports were in patients having previously experienced angioedema with an ACE-I. 87, 88 A number of the early reports occurred in patients with renal insufficiency. 87, 89 Over time, reports have appeared in which ARB-related angioedema has occurred either in patients not having previously been exposed to an ACE-I, or in those having previously received an ACE-I and not having developed angioedema. 90, 91 Recurrent episodes of angioedema have been reported in patients in whom the inciting ARB was not discontinued following the initial episode of angioedema. 92 As with ACE-Is, there can be a lag period of several months with an ARB before the appearance of angioedema. 90 The exact mechanism of ARB-related angioedema is unknown and, moreover, it is unclear as to what factors predispose a patient with ACE-I-related angioedema to the development of angioedema with an ARB, or what the exact frequency of its occurrence is. 91, 93 It is also unclear as to what degree sporadic idiopathic angioedema is falsely attributed to ARB therapy, simply because an ARB was being given at the time of the episode. ARB-related angioedema seems to occur rarely in clinical trials. For example, in the Losartan Intervention for Endpoints (LIFE) trial, there were six reported cases of angioedema in a total of 4,605 patients treated for four years with losartan (an incidence rate of 0.1%). In the atenolol-treatment limb of the same trial, in a total of 4,588 patients treated for four years, there were 11 episodes of angioedema (an incidence rate of 0.2%). 94 These data would suggest that, although angioedema can occur with an ARB, much of its occurrence is sporadic and not medication-specific. One other large-scale trial with ARBs was the Optimal Trial in Myocardial Infarction with the Angiotensin-II Antagonist Losartan (OPTIMAAL). Five thousand, four hundred and seventy-seven patients with confirmed acute myocardial infarction and heart failure during the acute phase,or a new Qwave anterior infarction, or reinfarction, were randomly assigned and titrated to a target dose of losartan (50 mg once-daily) or captopril (50 mg three times daily) as tolerated. In this trial, there were 10 (0.4%) and 22 (0.8%) cases of angioedema in the losartan and captopril treatment groups, respectively. 95 Despite the relatively benign nature of most angioedema episodes and the infrequency of angioedema cross-reactivity between an ACE-I and an ARB, these drugs cannot be used without some risk, albeit small. If ARB therapy is contemplated in a patient with prior ACE-I-related angioedema, there should be a reasonable justification for its use. Such justifications include the need to treat CHF, nephropathy states accompanied by proteinuria, high-risk cardiovascular patients, resistant hypertension responsive only to measures that interrupt RAAS activity, and/or multiple medication sensitivities requiring therapy with a medication devoid of side-effects. No doubt, additional therapeutic areas will emerge where the small risk of angioedema with ARB can be justified by the benefit of such therapy. 96
Anaphylactoid dialyser reactions
In 1990, the first cases of anaphylactoid dialyser reactions were described, occurring in patients dialysed with AN69 dialyser membranes. 97 These reactions were distinctive, occurring at the start of a haemodialysis session in patients being treated with an ACE-I. Since the original description of this entity, a number of corroborating reports have appeared that further define the nature of this phenomenon. [98] [99] [100] [101] Anaphylactoid reactions present as immediate hypersensitivity reactions and anaphylaxis, both of variable severity. These reactions have not been dialyser-or dialysate-specific, although they do occur more frequently with polyacrylonitrile (PAN) membranes. 102, 103 Reactions have ranged from mild itching to life-threatening systemic reac-tions, characterised by bronchospasm, hypotension, and cardiopulmonary collapse. 101 These reactions are abrupt, occurring within seconds to minutes of blood contact with the dialyser and often occur repetitively. 97 They are class-specific, since they have been described with virtually all ACE-Is. 97, 99 Although not specifically demonstrated to be dose-dependent, these anaphylactoid reactions are likely to be so. 104 The inability to show a convincing dose-related linkage with ACE-Is is probably related to different pre-dialysis dosing times and/or pharmacokinetic differences amongst the various ACE-Is.
This process likely relates to ACE-I-mediated perturbations in the bradykinin system. 98, 104, 105 PAN membranes are highly negatively charged, which facilitates contact activation of Hagemann factor at a greater rate than occurs with cuprophane membranes. Hagemann factor then promotes conversion of prekallikrein to kallikrein. Under these conditions of kallikrein activation, an earlier and more intense generation of bradykinin arises upon contact exposure of blood with PAN membranes. This process is merely amplified in the presence of an ACE-I. This process has now been shown to be bradykinin-related, in that it can be completely prevented by the prior administration of the bradykinin B 2 -receptor antagonist, icatibant. 104 To date, dialyserrelated anaphylactoid reactions have only been rarely observed to occur with ARBs. 17, 106, 107 Because of this,conventional practice in most dialysis units is to automatically convert ACE-I-treated patients to an ARB if a PAN membrane is being used.
Hyperkalaemia
Both ACE-Is and ARBs can cause hyperkalaemia, particularly in patients with chronic renal failure. 108 The risk of hyperkalaemia with either drug class is currently unknown in haemodialysis patients. A recent report notes that the use of an ACE-I or an ARB was associated with a significantly higher risk of hyperkalaemia in ESRD patients. This increased risk was present in anuric dialysis patients and in those with residual renal function. 109 This fact that anuric subjects developed hyperkalaemia more frequently when receiving either an ACE-I or an ARB would imply that these drug classes were diminishing the colonic secretion of potassium, which, is known to be increased in renal failure, 110 and/or were decreasing the transcellular inward migration of potassium, for which, there is evidence to support a role for aldosterone. 111 To date, there is insufficient information to distinguish these two drug classes in their propensity to cause hyperkalaemia in the ESRD patient undergoing haemodialysis.
Conclusions
The effective treatment of hypertension is an extremely important consideration in patients with ESRD.Virtually any drug class, with the possible exception of diuretics, can be used to treat ESRD-related hypertension. Despite there being such a wide range of treatment options, drugs which interrupt the RAAS axis are generally viewed as agents of choice in this population, even though the evidence in support of their preferential use is quite scanty. ACE-Is, and more recently ARBs, are the two drug classes most commonly employed to alter RAAS activity and thereby to effect BP control. ACE-Is are variably dialysed, with compounds such as captopril, enalapril, lisinopril and perindopril undergoing substantial cross-dialyser clearance. This property complicates the selection of a dose and the timing of administration for an ACE-I.
Furthermore,ACE-Is are recognised as having a range of non-pressor effects that are pertinent to patients with ESRD. Such effects include their ability to decrease thirst drive and to diminish erythropoiesis. ACE-Is also have a distinctive adverse effect profile. As is the case in non-renal failure patients, the ESRD patient can develop cough and, less frequently, angioneurotic oedema with an ACE-I. In the ESRD population, ACE-I use is also accompanied by so-called anaphylactoid dialyser reactions.ARBs are similar to ACE-Is in their capacity to lower BP. ARBs are not dialysable and thereby differ from a number of the ACE-Is. In addition, the adverse-effect profile for ARBs is nondescript, with cough and angioneurotic oedema rarely occurring. In patients with ESRD, ARBs are also not associated with anaphylactoid dialyser reactions.The nonpressor effects of ARBs, such as an influence on thirst drive and erythropoiesis, have not been explored in nearly the depth as those of ACE-Is. Although ACE-Is have not been compared directly to ARBs in patients with ESRD, ARBs possess pharmacokinetic and adverse-effect characteristics, which would favour their use in this population.
